Last reviewed · How we verify
Mycophenolate+Tacrolimus+Prednisone
This triple immunosuppressive regimen suppresses T-cell proliferation and activation to prevent organ rejection after transplantation.
This triple immunosuppressive regimen suppresses T-cell proliferation and activation to prevent organ rejection after transplantation. Used for Prevention of organ rejection in renal transplant recipients.
At a glance
| Generic name | Mycophenolate+Tacrolimus+Prednisone |
|---|---|
| Also known as | Myfortic, Tacrolimus, Prednisone |
| Sponsor | Fundação Pró Rim |
| Drug class | Immunosuppressive combination therapy |
| Target | T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate inhibits inosine monophosphate dehydrogenase to reduce T and B cell proliferation. Tacrolimus blocks calcineurin signaling to prevent T-cell activation and cytokine production. Prednisone provides broad anti-inflammatory and immunosuppressive effects. Together, these agents work synergistically to prevent allograft rejection.
Approved indications
- Prevention of organ rejection in renal transplant recipients
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Gastrointestinal disturbances
- Tremor
- Bone loss / osteoporosis
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (PHASE4)
- TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate+Tacrolimus+Prednisone CI brief — competitive landscape report
- Mycophenolate+Tacrolimus+Prednisone updates RSS · CI watch RSS
- Fundação Pró Rim portfolio CI